QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module XVI — Routine and Additional Risk Minimisation Measures

Test your understanding of the concepts covered by GVP Module XVI: Routine and Additional Risk Minimisation Measures.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A highly restrictive programme reduces exposure to a safety risk but causes substantial treatment delays and informal workarounds. How should this be considered?

The restrictions are automatically justified because any reduction in exposure outweighs all other considerations These effects are unintended consequences that should be included in the overall benefit-risk assessment Workarounds demonstrate that healthcare professionals are solely responsible for failure Treatment delays are outside the scope of risk minimisation evaluation

Question 2 of 10 What distinguishes an educational or safety-advice tool from routine product information?

It provides targeted information or instructions beyond routine product information because additional communication is necessary to manage the risk It contains promotional information intended to increase appropriate product use It is automatically required whenever the adverse reaction is serious It is intended to replace the SmPC and package leaflet

Question 3 of 10 A medication error occurs because a complex preparation process leads to incorrect concentration before administration. Which design principle is most relevant when selecting an additional RMM?

Direct the intervention primarily to the general public because all safety information should be publicly available Choose the most restrictive available control regardless of where the error occurs Target the person and step in the preparation or administration pathway where the error can be prevented Rely exclusively on a general description of the adverse reaction in the package leaflet

Question 4 of 10 Which documentation package would best support an inspection of a significant additional RMM?

Only the final educational leaflet Only records showing that the measure was approved The safety rationale, approved materials, dissemination and implementation records, evaluation evidence, deviations and subsequent decisions Only aggregate adverse-event counts without information about the intervention

Question 5 of 10 Which chain most completely captures the core design logic of Module XVI?

Seriousness, document production, distribution, archiving Safety concern, preventable mechanism, required action, responsible person, intervention, implementation, expected outcome and evaluation Product launch, promotion, sales monitoring, renewal Signal detection, regulatory approval, leaflet printing, programme closure

Question 6 of 10 When might one safety concern appropriately require multiple risk minimisation measures?

When the organisation wants to demonstrate a high volume of activity regardless of the causal pathway When different interventions are needed to influence separate points in the pathway leading to the adverse outcome Only when each measure is directed to exactly the same audience and action Only when routine product information has been removed

Question 7 of 10 Which evaluation approach best matches a measure intended to reduce inappropriate prescribing?

Counting only the number of materials printed Assessing whether the material contains scientifically accurate references Using a behavioural indicator such as prescribing data, supported where useful by qualitative investigation Measuring only the number of adverse reactions reported before launch

Question 8 of 10 A company proposes adding several restrictions to a control programme because greater complexity is assumed to provide greater protection. What is the most appropriate regulatory interpretation?

Complexity is inherently evidence of a stronger risk-minimisation system Each additional requirement should be justified because complexity can create non-compliance, workarounds and delays Control programmes should always contain at least three separate interventions A complex programme does not require effectiveness evaluation if all steps are documented

Question 9 of 10 Which statement best describes the regulatory logic for selecting an additional risk minimisation measure?

Any serious safety concern automatically requires an additional risk minimisation programme Additional measures are selected when routine measures are insufficient to manage a defined safety concern and a proportionate intervention is needed Additional measures replace routine product information once a risk becomes clinically important Additional measures are primarily selected according to the communication format most familiar to the marketing authorisation holder

Question 10 of 10 A risk depends on a prescribing decision, but the proposed communication is sent only after dispensing. What is the main design concern?

The communication is necessarily routine risk minimisation The intervention may reach the recipient after the critical decision point and therefore have limited preventive value Post-dispensing communication is always prohibited The risk must be managed only through a pregnancy prevention programme

Knowledge Assessment: GVP Module XVI — Routine and Additional Risk Minimisation Measures

Cookie Settings